Market Overview

Check-Cap Announces Final Results From Post-CE Approval Study Of C-Scan

Check-Cap Announces Final Results From Post-CE Approval Study Of C-Scan

Check-Cap (NASDAQ: CHEK) announced positive final results from its recently completed post-CE approval study evaluating the clinical performance and safety of the C-Scan system.

C-Scan is a preparation-free capsule based screening method for the prevention of colorectal cancer through the detection of precancerous polyps.

In total, 142 patients enrolled in the study and after factoring in technical and physiological dropouts and protocol violations, the number of evaluable patients was 90. Check-Cap says no serious adverse events were reported, and the adverse events were mild in severity.

Check-Cap shares traded higher by 24% at $2.70 in Tuesday’s pre-market session. The stock has a 52-week range between $4.50 and $1.62.

Related Links:

FDA Grants Fast Track Designation For Prevail's Parkinson's Treatment

Sol-Gel Technologies Shares Positive Results For Skin Breakout Cream

Posted-In: News Health Care General Best of Benzinga


Related Articles (CHEK)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Cohu Warns Of Delays, Cites Huawei Restrictions Impact

Kinahan Says Millennials Are Buying The Stocks They Know, Like Beyond Meat And Tesla